Elbrus Capital Fund invests in the development of Active Component

«Elbrus Capital II», the leading private equity fund focused on Russia and the CIS, announced an investment in «Acticomp».

After the Fund enters the Company's capital, the controlling stake will remain with its founders, Alexandr Semenov and Ziyuvuddin Khodzhayev.

The received investment company «Acticomp» is planning to direct to the implementation of a project to create a new largest plant in Europe for the production of active pharmaceutical substances in Pushkin (St. Petersburg). A project worth about 2 billion rubles was first announced a year ago when the Agreement of Intent was signed between «Acticomp» JSC and the Government of St. Petersburg at the St. Petersburg International Economic Forum in June 2017. The launch of the first stage of production is planned in the first half of 2019, and full commissioning in 2020.

Alexander Savin, Senior Partner of the «Elbrus Capital» funds commented on the deal: «We highly appreciate the prospects for the development of the pharmaceutical substances sector in Russia. The long-term trend towards localization of medicines production in Russia contributes to the growth of demand for Russian-made substances. At «Acticomp», we see the industry leader and we are ready to provide maximum support to the founders and the management team in implementing the Company's further growth strategy».

Alexander Semenov, co-founder and President of «Acticomp»: “The mission of «Acticomp» is to supply Russian and international manufacturers of pharmaceutical products with affordable materials with guaranteed high quality at the level of the best global manufacturers. We are pleased to be part of the «Elbrus Capital» fund project in our company, which we see as a reliable partner and support for the further development of the Company, which plans to actively expand the product line, develop production capacities in cooperation with leading global manufacturers and, as a result, significant increase in the supply of pharmaceutical substances to the markets of Russia, Europe and Latin America ".

«EY» company has acted as a consultant to «Elbrus Capital» in conducting comprehensive financial, tax and legal expertise, legal structuring and support of the transaction; The international company «IQVIA» carried out the commercial audit. On the part of «Acticomp» and its founders, the law firm «Duvernoix Legal» took an active part in the preparation of the transaction, and investment bank «Novus Capital» acted as a financial consultant.